Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Ingenol Disoxate in Actinic Keratosis
NCT03115476Phase 3Terminated
- Sponsor
- LEO Pharma
- Start
- Jun 2017
- Primary completion
- Mar 2018
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of ingenol disoxate in actinic keratosis (AK), sponsored by LEO Pharma. Started Jun 2017; status: terminated.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03115476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115476.